A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Latest Information Update: 27 May 2024
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms PLEIADES
- Sponsors Janssen Research & Development; Janssen-Cilag
- 22 May 2024 Status changed from active, no longer recruiting to completed.
- 30 Jan 2024 Planned End Date changed from 30 Nov 2023 to 29 Feb 2024.
- 08 Nov 2023 Planned End Date changed from 29 Sep 2023 to 30 Nov 2023.